Review on mannose receptor as an endocytic receptor in antigen delivery that is co-
expressed with the microRNA miR-511-3p encoded within the Mrc1 gene. The MR is a …

The pathogenesis of inhibitory antibodies has been the focus of major scientific interest over
the last decades, and several studies on underlying immune mechanisms and risk factors for …

Frequent infusions of intravenous factor VIII (FVIII) are required to prevent bleeding
associated with hemophilia A. To reduce the treatment burden, recombinant FVIII with a …

Development of neutralizing antibodies against biotherapeutic agents administered to
prevent or treat various clinical conditions is a longstanding and growing problem faced by …

Anti‐drug antibody formation following factor VIII (FVIII) replacement therapy is the most
important treatment‐related complication in patients with severe haemophilia A. A significant …

Interaction of factor VIII (FVIII) with von Willebrand factor (VWF) is mediated by the VWF D′
D3 domains and thrombin-mediated release is essential for hemostasis after vascular injury …

Interactions between vascular smooth muscle cells (VSMCs), endothelial cells (ECs),
pericytes (PCs) and macrophages (MФ), the major components of blood vessels, play a …

Recent improvement in modern analytical technologies has stimulated an explosive growth
in the study of glycobiology. In turn, this has lead to a richer understanding of the crucial role …

Essentials• CLEC4M is an endocytic receptor for factor FVIII.• CLEC4M interacts with FVIII in
a VWF‐dependent and independent manner.• CLEC4M binds to mannose‐containing …

Immunogenicity is an important consideration in the licensure of a therapeutic protein
because the development of neutralizing anti-drug antibodies (ADAs) can affect both safety …